NCT05145062View on ClinicalTrials.gov

Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

Enrolling by invitationOBSERVATIONAL
Enrollment

12

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

July 14, 2038

Study Completion Date

July 14, 2038

Conditions
Blood and Lymphatic Diseases
Interventions
DRUG

BIVV003

Solution for intravenous administration

DRUG

ST-400

Solution for intravenous administration

Trial Locations (7)

30329

Children's Healthcare of Atlanta, Atlanta

48201

Karmanos Cancer Institute, Detroit

48202

Henry Ford Health System, Detroit

55455

University of Minnesota, Minneapolis

94609

UCSF Benioff Children's Hospital, Oakland

95817

University of California Davis Health System, Sacramento

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Sangamo Therapeutics

INDUSTRY